Business Description
Tvardi Therapeutics is a clinical-stage drug development company based in Sugar Land, Texas, focused on creating treatments for serious inflammatory and proliferative diseases. The company's work centers on blocking a specific protein called STAT3, which plays a key role in conditions where current treatment options fall short. Its two lead medicines, TTI-101 and TTI-109, are both taken by mouth and are currently being tested in clinical trials for diseases including lung scarring and liver cancer. Founded in 2017, Tvardi is working to bring new options to patients who have few effective therapies available today.
